Skip to main content
SpringerLink
Log in

Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder (复方青黄散) in Patients with Myelodysplastic Syndromes

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objectives

To investigate the relationship between gene mutations and response to Compound Qinghuang Powder (复方青黄散, CQHP) in patients with myelodysplastic syndrome (MDS).

Methods

Forty-three MDS patients were genotyped by ultra-deep targeted sequencing and the clinical data of patients were collected and the relationship between them was analyzed.

Results

Up to 41.86% of patients harbored genet mutations, in most cases with more than one mutation. The most common mutations were in SF3B1, U2AF1, ASXL1, and DNMT3A. After treatment with CQHP, about 88.00% of patients no longer required blood transfusion, or needed half of prior transfusions.

Conclusions

CQHP is an effective treatment for patients with MDS, especially those with gene mutations in SF3B1, DNMT3A, U2AF1, and/or ASXL1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:831–841.

    Article  PubMed  Google Scholar 

  2. Papaemmanuil E, Gerstung M, Malcovati L. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616–3627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Haferlach T, Nagata Y, Grossmann V. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241–247.

    Article  CAS  PubMed  Google Scholar 

  4. Zhang L, Padron E, Lancet J. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res 2015;39:6–17.

    Article  CAS  PubMed  Google Scholar 

  5. Smith AE, Mohamedali AM, Kulasekararaj A. Next generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010;116:3923–3932.

    Article  CAS  PubMed  Google Scholar 

  6. Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China. Chin J Integr Med 2010;16:368–477.

    Article  CAS  PubMed  Google Scholar 

  7. Ma JL, Qu WW, Hu XM. Arsenic preparation for application in the treatment of myelodysplastic syndrome. Chin J Clin (Electr ed, Chin) 2012;6:149–150.

    Google Scholar 

  8. Hu XM, Wang HZ, Mao C, Liu C, Li L, Zheng CM, et al. Clinical significance of trisomy 8 and monosomy 7/7q deletion in myelodysplastic syndrome. J Clin Hematol (Chin) 2006;19:340–343.

    Google Scholar 

  9. Hu XM, Ma JL, Ma R. Selectivity of treatment to clone category in patients with myelodysplastic syndromes. J Leuk Lymph (Chin) 2011;20:759–761.

    Google Scholar 

  10. Ma JL, Qu WW, Hu XM. Correlationship of clonal selection of treatment with arsenious compound formula Qinghuang Powder with in vivo effects of arsenic in patients with myelodysplastic syndrome. Chin J Inf Tradit Chin Med (Chin) 2013;20:5–8.

    Google Scholar 

  11. Sun SZ, Ma R, Hu XM, Yang XH, Xu YG, Wang HG, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic. Evid Based Complement Alternat Med 2012;2012:969476.

    Google Scholar 

  12. Vanlet P, Horny HP, Bennet JM, Christa F, Ulrich G, Peter G, et al. Definitions and standards in the diagnosis and treatment of myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727–736.

    Article  Google Scholar 

  13. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008:88–93.

    Google Scholar 

  14. Shaffer LG, Tommerup N, eds. An international system for human cytogenetic nomenclature. Basel: S. Karger Publishers; 2005.

    Google Scholar 

  15. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497–1503.

    Article  CAS  PubMed  Google Scholar 

  16. Zheng XY, ed. Guidelines for the clinical research of traditional Chinese medicine (Trial). Beijing: China Medical Science and Technology Press; 2002:19–20.

    Google Scholar 

  17. Hu XM, Ma R, Xu YG, GUO XQ, Xu S, Liu F, et al. Application of Qinghuang Powder in treating hematologic malignancies. Int J Tradit Chin Med (Chin) 2011;33:568–570.

    Google Scholar 

  18. Xu S, Ma R, Hu XM. Clinical observation on Qinghuang Powder for treatment of 31 cases of myelodysplastic syndrome. J Tradit Chin Med (Chin) 2006;47:514–516.

    Google Scholar 

  19. Xu S, Hu XM, Xu YG, Yang XH, Wang HZ, Liu F, et al. Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing Shen and strenghening Pi. Chin J Integr Chin West Med (Chin) 2008;28:216–219.

    Google Scholar 

  20. Liu F, Guo XQ, Hu XM, Xu YG, Wang HZ, Yang XH, et al. Effect of Qinghuang Powder in treating 36 patients with myelodysplastic syndrome. J Tradit Chin Med (Chin) 2011;52:241–242.

    Google Scholar 

  21. Xu S, Ma R, Hu XM, Xu YG, Yang XH, Wang HZ, et al. Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. Chin J Integr Med 2011;17:834–839.

    Article  PubMed  Google Scholar 

  22. Wang Y, Fang S, Song MM, Hu XM. Safety of compound Qinghuang powder in patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2014;37:1074–1077.

    Google Scholar 

  23. Wang Y, Fang S, Deng ZY, Song MM, Ma JL, Yang XP, et al. Compound Qinghuang Powder in the treatment of patients with myelodysplastic syndromes. Int J Tradit Chin Med (Chin) 2015;37:1091–1095.

    Google Scholar 

  24. Wang FR, Lou YQ, Lu DP. Study on clinical pharmacokinetics of oral Tetraarsenic tetrasulfide. Chin J Hematol (Chin) 2005;26:44–46.

    Google Scholar 

  25. Ni JH, Chen GQ, Shen ZX, Li XS, Liu HW, Huang YT, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin J Hematol (Chin) 1997;18:250–253.

    CAS  Google Scholar 

  26. Hu XM, Tanaka S, Onda K, Yuan B, Toyoda H, Ma R, et al. Arsenic disulfide induced apoptosis and concurrently promoted erythroid differentiation in cytokine-dependent myelodysplastic syndrome-progressed leukemia cell line F-36p with complex karyotype including monosomy 7. Chin J Integr Med 2014;20: 387–393.

    Article  CAS  PubMed  Google Scholar 

  27. Hu XM, Yuan B, Tanaka S, Song MM, Onda K, Tohyama K, et al. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines. Hematology 2014;19:352–360.

    Article  CAS  PubMed  Google Scholar 

  28. Hu XM, Yuan B, Song MM, Onda K, Tanaka S, Toyoda H, et al. Dose-dependent biphasic effects of arsenic disulfide on differentiation and apoptosis of HL-60 cells. Curr Topics Pharmacol (Chin) 2014;17:13–25.

    Google Scholar 

  29. Hu XM, Yuan B, Tanaka S, Zhou QB, Onda K, Toyoda H, et al. Involvement of oxidative stress associated with glutathione depletion and p38 MAPK activation in arsenic disulfide-induced differentiation in HL-60 cells. Leuk Lymphom 2014;55:392–404.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China

    Pan Zhao, Zhong-yang Deng, Ming-jing Wang & Xiao-mei Hu

  2. Annoroad Gene Technology Co. Ltd., Beijing, 100176, China

    Jun-bin Liang, Jia-yue Qin & Chong-jian Chen

Authors
  1. Pan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-bin Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhong-yang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming-jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jia-yue Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chong-jian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao-mei Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chong-jian Chen or Xiao-mei Hu.

Additional information

Supported by the Beijing Municiple Science and Technology Commission (No. Z141100006014003), the National Natural Science Foundation of China (No. 81673821), and the Special Research Foundation of Central Level Public Scientific Research Institutes (No. ZZ10-016)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, P., Liang, Jb., Deng, Zy. et al. Association of Gene Mutations with Response to Arsenic-Containing Compound Qinghuang Powder (复方青黄散) in Patients with Myelodysplastic Syndromes. Chin. J. Integr. Med. 25, 409–415 (2019). https://doi.org/10.1007/s11655-018-2977-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-018-2977-3

Keywords

Search

Navigation